Your body may release less growth hormone as a result
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
30 mg/mL tirzepatide conversion chart: The decimal unit values make this concentration challenging for precise dosing at the starter level
Transformations worth watching
Compounded drugs are produced by licensed pharmaceutical companies in cases where commercially manufactured drugs are not available, are scarce or are unaffordable
Excess drinking can lead to alcohol poisoning, which is a medical emergency